Hedyeh Ebrahimi

51.1k total citations
25 papers, 364 citations indexed

About

Hedyeh Ebrahimi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Hedyeh Ebrahimi has authored 25 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in Hedyeh Ebrahimi's work include Renal cell carcinoma treatment (4 papers), Prostate Cancer Diagnosis and Treatment (3 papers) and Cancer Genomics and Diagnostics (3 papers). Hedyeh Ebrahimi is often cited by papers focused on Renal cell carcinoma treatment (4 papers), Prostate Cancer Diagnosis and Treatment (3 papers) and Cancer Genomics and Diagnostics (3 papers). Hedyeh Ebrahimi collaborates with scholars based in United States, Iran and Canada. Hedyeh Ebrahimi's co-authors include Farhad Pishgar, Sahar Saeedi Moghaddam, Amir Ali Sohrabpour, Mohammadreza Naderian, Erfan Amini, Christina Fitzmaurice, Farshad Farzadfar, Mohammad Reza Nowroozi, Arya Aminorroaya and Yasna Rostam‐Abadi and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Hedyeh Ebrahimi

20 papers receiving 359 citations

Peers

Hedyeh Ebrahimi
Neeta K. Venepalli United States
Xue Han China
Yun-Jau Chang Taiwan
Ersin Özaslan Türkiye
Wenqiang Wei China
Zheng Long China
Yasuhiro Toyoda Japan
Ariel Yuhan Ong United Kingdom
Victoria Huynh United States
James Cucinelli United States
Neeta K. Venepalli United States
Hedyeh Ebrahimi
Citations per year, relative to Hedyeh Ebrahimi Hedyeh Ebrahimi (= 1×) peers Neeta K. Venepalli

Countries citing papers authored by Hedyeh Ebrahimi

Since Specialization
Citations

This map shows the geographic impact of Hedyeh Ebrahimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hedyeh Ebrahimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hedyeh Ebrahimi more than expected).

Fields of papers citing papers by Hedyeh Ebrahimi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hedyeh Ebrahimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hedyeh Ebrahimi. The network helps show where Hedyeh Ebrahimi may publish in the future.

Co-authorship network of co-authors of Hedyeh Ebrahimi

This figure shows the co-authorship network connecting the top 25 collaborators of Hedyeh Ebrahimi. A scholar is included among the top collaborators of Hedyeh Ebrahimi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hedyeh Ebrahimi. Hedyeh Ebrahimi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chawla, Neal Shiv, Nicholas Salgia, Ameish Govindarajan, et al.. (2025). Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma. JCO Precision Oncology. 9(9). e2400947–e2400947.
2.
Ebrahimi, Hedyeh, Luís Meza, Nazlı Dizman, et al.. (2025). Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.. Journal of Clinical Oncology. 43(5_suppl). 543–543. 1 indexed citations
3.
Li, Xiaochen, A. Lee, Hedyeh Ebrahimi, et al.. (2025). Assessing global disparities in clinical trial availability for renal cell carcinoma (RCC).. Journal of Clinical Oncology. 43(5_suppl). 449–449.
4.
Ebrahimi, Hedyeh, Luís Meza, Regina Barragán-Carrillo, et al.. (2025). Long-term clinical outcomes with nivolumab/ipilimumab with or without Clostridium butyricum MIYAIRI588 in metastatic renal cell carcinoma (mRCC): A randomized phase Ib clinical trial.. Journal of Clinical Oncology. 43(16_suppl). 4550–4550. 1 indexed citations
5.
Ebrahimi, Hedyeh, Regina Barragán-Carrillo, Zeynep Büşra Zengin, et al.. (2025). Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).. Journal of Clinical Oncology. 43(16_suppl). 5087–5087.
6.
Zarif, Talal El, Naveen S. Basappa, Hedyeh Ebrahimi, et al.. (2024). Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology. 42(16_suppl). 4514–4514. 5 indexed citations
7.
Barragán-Carrillo, Regina, Nazlı Dizman, Xiaochen Li, et al.. (2024). Adherence to American Society of Clinical Oncology (ASCO) language of respect (LoR) guidelines in ASCO Annual Meeting prostate cancer (PCa) abstracts.. Journal of Clinical Oncology. 42(4_suppl). 94–94.
8.
Chehrazi‐Raffle, Alex, Hanna Tukachinsky, Smruthy Sivakumar, et al.. (2023). Unique Spectrum of Activating BRAF Alterations in Prostate Cancer. Clinical Cancer Research. 29(19). 3948–3957. 8 indexed citations
9.
Ebrahimi, Hedyeh, Masoud Masinaei, Arya Aminorroaya, et al.. (2023). Risk of incident cardiovascular diseases at national and subnational levels in Iran from 2000 to 2016 and projection through 2030: Insights from Iran STEPS surveys. PLoS ONE. 18(8). e0290006–e0290006. 3 indexed citations
10.
Dizman, Nazlı, Khyatiben V. Pathak, Marice Alcantara, et al.. (2023). Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 41(16_suppl). 4556–4556.
11.
Ebrahimi, Hedyeh, Luís Meza, Jasnoor Malhotra, et al.. (2023). Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.. Journal of Clinical Oncology. 41(17_suppl). LBA104–LBA104. 18 indexed citations
12.
Urban, Lara, Mariana De Niz, Hedyeh Ebrahimi, et al.. (2022). eLife’s new model and its impact on science communication. eLife. 11. 2 indexed citations
13.
Mehta, Devang, Yaw Bediako, Charlotte M. de Winde, et al.. (2020). Ways to increase equity, diversity and inclusion. eLife. 9. 7 indexed citations
14.
Ebrahimi, Hedyeh, Farhad Pishgar, Moein Yoosefi, et al.. (2019). Insulin pen use and diabetes treatment goals: A study from Iran STEPS 2016 survey. PLoS ONE. 14(8). e0221462–e0221462. 14 indexed citations
15.
Mohajer, Bahram, Nooshin Abbasi, Farhad Pishgar, et al.. (2018). HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East North Africa region: A systematic review and meta-analysis. Journal of Neuroimmunology. 321. 117–124. 11 indexed citations
16.
Ebrahimi, Hedyeh, Mohammadreza Naderian, & Amir Ali Sohrabpour. (2018). New Concepts on Reversibility and Targeting of Liver Fibrosis; A Review Article. Middle East Journal of Digestive Diseases. 10(3). 133–148. 29 indexed citations
17.
Pishgar, Farhad, Hedyeh Ebrahimi, Sahar Saeedi Moghaddam, Christina Fitzmaurice, & Erfan Amini. (2017). Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. The Journal of Urology. 199(5). 1224–1232. 65 indexed citations
18.
19.
Ebrahimi, Hedyeh, Mohammadreza Naderian, & Amir Ali Sohrabpour. (2016). New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. Middle East Journal of Digestive Diseases. 8(3). 166–178. 42 indexed citations
20.
Gohari, Mahmood Reza, et al.. (2013). Thyroid function in pregnant women: iodine deficiency after iodine enrichment program. Gynecological Endocrinology. 29(6). 596–599. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neeta K. Venepalli Breakdown of academic impact, for papers by Xue Han Breakdown of academic impact, for papers by Yun-Jau Chang Breakdown of academic impact, for papers by Ersin Özaslan Breakdown of academic impact, for papers by Wenqiang Wei Breakdown of academic impact, for papers by Zheng Long Breakdown of academic impact, for papers by Yasuhiro Toyoda Breakdown of academic impact, for papers by Ariel Yuhan Ong Breakdown of academic impact, for papers by Victoria Huynh Breakdown of academic impact, for papers by James Cucinelli
Rankless by CCL
2026